Apodemus hypothesizes that chronic viral infections are involved in the development and progression of several major human diseases including neurodegenerative diseases. Apodemus first clinical trial studied the effect of Apovir (a combination of pleconaril and ribavirin) in patients with Alzheimer’s disease and was completed in June 2016. The outcome of the trial has been found to be inconclusive due to a large drop-out rate that made data difficult to interpret. In order to test the hypothesis properly Apodemus AB started a new clinical trial in July 2018 to evaluate the effect of pleconaril on the progression of Alzheimer’s disease.
Alzheimer’s disease is the most common form of dementia. It has been estimated that there are approximately 26.6 million sufferers of Alzheimer’s disease worldwide. Most often, Alzheimer’s disease is diagnosed in people over 65 years of age. There are currently no available treatments that can stop or reverse the progression of the disease.
In developed countries, Alzheimer’s disease is one of the most costly diseases to society.
For more information about dementias please see:
Alzheimer association www.alz.org
Pressmeddelande 12 februari 2014, Ny studie om Alzheimer har påbörjats, klicka här
Läs mer om Alzheimer studien på Karolinska Trial Alliance hemsida, klicka här
Se nyhetsinslag i TV4 den 12 februari 2014, Alzheimer kan vara virus
Läs artikel i Dagens medicin den 11 februari 2014, Virushämmare testas mot alzheimer